The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 14, 2013
Filed:
May. 21, 2007
Frank Dininno, Barnegat, NJ (US);
Milton L. Hammond, Somerville, NJ (US);
Kevin Dykstra, West Milford, NJ (US);
Seongkon Kim, Holmdel, NJ (US);
Qiang Tan, Westfield, NJ (US);
Katherine Young, Metuchen, NJ (US);
Jeffrey Donald Hermes, Warren, NJ (US);
Helen Chen, Marlboro, NJ (US);
Stephane Raeppel, St. Lazare, CA;
Michael Mannion, Montreal, CA;
Frederic Gaudette, Laval, CA;
Arkadii Vaisburg, Kirkland, CA;
Jubrail Rahil, Dollard des Ormeaux, CA;
Nafsika Georgopapadakou, Vaudreuil, CA;
Nancy Z. Zhou, Kirkland, CA;
Frank Dininno, Barnegat, NJ (US);
Milton L. Hammond, Somerville, NJ (US);
Kevin Dykstra, West Milford, NJ (US);
Seongkon Kim, Holmdel, NJ (US);
Qiang Tan, Westfield, NJ (US);
Katherine Young, Metuchen, NJ (US);
Jeffrey Donald Hermes, Warren, NJ (US);
Helen Chen, Marlboro, NJ (US);
Stephane Raeppel, St. Lazare, CA;
Michael Mannion, Montreal, CA;
Frederic Gaudette, Laval, CA;
Arkadii Vaisburg, Kirkland, CA;
Jubrail Rahil, Dollard des Ormeaux, CA;
Nafsika Georgopapadakou, Vaudreuil, CA;
Nancy Z. Zhou, Kirkland, CA;
MethylGene Inc., Montreal, CA;
Abstract
This invention provides novel β-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammomium groups. The compounds inhibit three classes of β-lactamases and synergize the antibacterial effects of β-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the β-lactam antibiotics as a result of the presence of the β-lactamases.